JPH0363356B2 - - Google Patents
Info
- Publication number
- JPH0363356B2 JPH0363356B2 JP58116149A JP11614983A JPH0363356B2 JP H0363356 B2 JPH0363356 B2 JP H0363356B2 JP 58116149 A JP58116149 A JP 58116149A JP 11614983 A JP11614983 A JP 11614983A JP H0363356 B2 JPH0363356 B2 JP H0363356B2
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- pta5001
- restriction enzyme
- added
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013612 plasmid Substances 0.000 claims description 54
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 244000283763 Acetobacter aceti Species 0.000 description 12
- 235000007847 Acetobacter aceti Nutrition 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 229960000723 ampicillin Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000007221 ypg medium Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108010069941 DNA receptor Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 210000003370 receptor cell Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000589236 Gluconobacter Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- -1 PH7.8) Chemical compound 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000187135 Streptomyces albus G Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
Description
【発明の詳細な説明】
本発明は、酢酸菌ベクターとしてきわめて有用
なプラスミドpTA5001(A)に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to plasmid pTA5001(A), which is extremely useful as an acetic acid bacterium vector.
更に詳細には、本発明は、制限酵素Xho Iに
よる認識部位をただ1ケ所有し、かつ酢酸菌への
移入が容易なプラスミドpTA5001(A)に関するも
のである。 More specifically, the present invention relates to plasmid pTA5001(A), which possesses only one recognition site for the restriction enzyme Xho I and is easily transferred to acetic acid bacteria.
従来、酢酸菌由来のプラスミドに関しては、ア
セトバクター、アセチNo.1023が分子量17×106ダ
ルトンのプラスミドpTA5001(Agric.Biol.
Chem.46(2)、381〜389、1982)を持つことを及び
グルコノバクター属細菌(醗酵工学雑誌、61(1)、
15−18、1983)の持つプラスミドなどの報告があ
つた。 Conventionally, regarding plasmids derived from acetic acid bacteria, Acetobacter aceti No. 1023 has a plasmid pTA5001 (Agric.Biol.
Chem.46(2), 381-389, 1982) and Gluconobacter bacteria (Fermentation Engineering Journal, 61(1),
15-18, 1983) were reported.
本発明者らは、このプラスミドpTA5001を詳
細に研究したところ、実際は2ケのプラミスドの
混在物であることを知り、更に2ケのプラスミド
の制限酵素開裂地図の作成を完成させ、その用途
を詳細に検討したところ、いずれのプラスミドも
制限酵素Xho Iによるう認識部位をただ1ケ所
有し、かつ酢素菌への移入の容易なすぐれたベク
ターであることを認識し、本発明を完成するに至
つた。 After studying this plasmid pTA5001 in detail, the present inventors learned that it was actually a mixture of two plasmids, and further completed the creation of restriction enzyme cleavage maps for the two plasmids and detailed their uses. Upon further investigation, we realized that each plasmid possesses only one recognition site for the restriction enzyme Xho I and is an excellent vector that can be easily transferred into acetic acid bacteria. I've reached it.
本発明は23.5Kbの分子量で、第1図の制限酵
素開裂地図で示されるプラスミドpTA5001(A)に
関する。 The present invention relates to plasmid pTA5001(A), which has a molecular weight of 23.5 Kb and is shown in the restriction enzyme cleavage map of FIG.
本発明のプラスミドpTA5001(A)とプラスミド
pTA5001(B)は同時にアセトバクター・アセチNo.
1023に存在し、該菌よりまず両者の混在物として
分離することができる。 Plasmid pTA5001(A) of the present invention and plasmid
pTA5001(B) is also Acetobacter aceti No.
1023, and can be isolated from this bacterium as a mixture of both.
アセトバクター・アセチNo.1023は酢酸醗酵醪か
ら単位・同定されたものであり(Agric.Biol.
Chem.、44(12)、1901〜2906、1980)、プラスミ
ドpTA5001(A)及びプラスミドpTA5001(B)を含ん
だまま微工研にFERM P−7122として寄託され
ている。 Acetobacter aceti No. 1023 was identified as a unit from acetic acid fermentation mash (Agric.Biol.
Chem., 44(12), 1901-2906, 1980), and has been deposited as FERM P-7122 at FIKEN, containing plasmid pTA5001(A) and plasmid pTA5001(B).
アセトバクター・アセチNo.1023は菌学的性質に
おいてバージイ第8版のアセトバクター・アセチ
の菌学的性質の記載とよく一致し、更に酢酸耐性
及びエタノール酸化能を有することで特徴的であ
り、Acetobacter aceti No.1023(Acer、Eth++)
と表示されることもある。 The mycological properties of Acetobacter aceti No. 1023 closely match the description of the mycological properties of Acetobacter aceti in the 8th edition of Virgil, and it is further characterized by having acetic acid resistance and ethanol oxidation ability. Acetobacter aceti No.1023 (Ace r , Eth ++ )
may also be displayed.
アセトバクター・アセチNo.1023は、例えば通常
的には下記のYPG培地で培養され、また形質転
換株の検出にはYPG培地に抗生物質等の薬剤を
適当な濃度となるように、例えばアンピシリンを
50μg/mlの濃度となるように、添加したものを
用いて培養される。 Acetobacter aceti No. 1023 is usually cultured in the following YPG medium, for example, and to detect transformed strains, the YPG medium is supplemented with drugs such as antibiotics to an appropriate concentration, such as ampicillin.
The cells are cultured using the added material at a concentration of 50 μg/ml.
(YPG培地)
イースト エキストラクト 0.5%
ポリペプトン 0.2%
グルコース 3.0%
寒天(固定培地の場合) 2.0%
PH=6.5
アセトバクター・アセチNo.1023はYPG液体培
地で、30℃で24〜36時間振とう培養し、培養液を
遠心分離処理して集菌される。菌体は緩衝液で十
分洗浄し、緩衝液に懸濁され、これにリゾチーム
が添加され、溶菌される。溶菌液には界面活性剤
及び食塩が添加され、静置後遠心分離し、上清に
ポリエチレングリコールが添加され、静置後遠心
分離し沈澱物を得る。この沈澱物を緩衝液に溶解
し、エチジウムブロマイドを加え、更に塩化セシ
ウムを加え、密度を1.57に合わせ、密度勾配遠心
分離を行こなう。遠心分離後、遠心チユーブに紫
外線ランプで365nmの紫外線照射により、染色
体バンドの下に出たバンドを分散する。(YPG medium) Yeast extract 0.5% Polypeptone 0.2% Glucose 3.0% Agar (for fixed medium) 2.0% PH = 6.5 Acetobacter aceti No. 1023 was cultured in YPG liquid medium with shaking at 30℃ for 24 to 36 hours. Then, the culture solution is centrifuged to collect bacteria. The bacterial cells are thoroughly washed with a buffer solution, suspended in the buffer solution, lysozyme is added thereto, and the cells are lysed. A surfactant and salt are added to the lysate, and after being allowed to stand, it is centrifuged. Polyethylene glycol is added to the supernatant, and after being allowed to stand, it is centrifuged to obtain a precipitate. This precipitate is dissolved in a buffer solution, ethidium bromide is added, cesium chloride is further added, the density is adjusted to 1.57, and density gradient centrifugation is performed. After centrifugation, the centrifugation tube is irradiated with 365 nm ultraviolet light using an ultraviolet lamp to disperse the bands below the chromosome bands.
ここで得らえるバンドにはプラスミド
pTA5001(A)とプラスミドpTA5001(B)が混在して
いる。 The band obtained here contains plasmid
pTA5001(A) and plasmid pTA5001(B) are mixed.
混在する2つのプラスミドは制限酵素による解
析の結果、はじめて2種類のほぼ同一分子量のプ
ラスミドの混在物であることが明らかとなつたも
のである。 As a result of restriction enzyme analysis, it was revealed for the first time that the two mixed plasmids were a mixture of two types of plasmids with approximately the same molecular weight.
プラスミドpTA5001(A)の分子量は23.5Kbで、
制限酵素開裂地図は第1図に示される。 The molecular weight of plasmid pTA5001(A) is 23.5Kb,
The restriction enzyme cleavage map is shown in FIG.
第1図に示される略記号の意味は次の通りであ
る。 The meanings of the abbreviations shown in FIG. 1 are as follows.
E:coR I:Escherichia coli RY13
給源の制限酵素
S:Sal I:Streptomyces albus G
給源の制限酵素
X:Xho I:Xanthomonas holcicola
給源の制限酵素
本発明のプラスミドpTA5001(A)はXho Iによ
つてただ1ケ所のみ切断されることによつてきわ
めて特徴的であつて、この切断部位の他のプラス
ミド断片や染色体断片を導入するのがきわめて容
易である。E: coR I: Escherichia coli RY13 source restriction enzyme S: Sal I: Streptomyces albus G source restriction enzyme It is very distinctive because it is cut at only one site, and it is extremely easy to introduce other plasmid fragments or chromosome fragments at this cut site.
本発明のプラスミドpTA5001(A)は酢酸菌ベク
ターとして使用するのに好適である。 Plasmid pTA5001(A) of the present invention is suitable for use as an acetic acid bacterium vector.
即ち、プラスミドpTA5001(A)にプラスミド断
片又は染色体断片を導入したものは、酢酸菌(ア
セトバクター属菌、グルコノバクター属菌)に容
易に移入することができ、酢酸菌の形質転換及
び/又は物質生産に新たな画期的手法を提供する
ものである。 That is, the plasmid pTA5001(A) into which a plasmid fragment or chromosome fragment has been introduced can be easily transferred to acetic acid bacteria (Acetobacter spp., Gluconobacter spp.), and can be used for transformation of acetic acid bacteria and/or It provides a new and innovative method for material production.
次に本発明の実施例を示す。 Next, examples of the present invention will be shown.
実施例 1
DNA受容菌体の調製
アセトバクター・アセチ No.1023、FERM P
−7122より100μg/ml濃度のニトロソグアニジ
ン(NTG)変異処理によつて得られたプロリン
要求性(Pro-)の親株であるアセトバクター・
アセチ10−8(Acer、Eth++、Pro-)から自然変
異によつて得た酢酸耐性およびエタノール酸化能
が低下、欠失(Acess、Eth-)し、かつ、ストレ
プトマイシン耐性(Strrの菌株であるアセトバク
ター・アセチ10−80S1(Acess、Eth-、Pro-、
Strr)を500ml板口フラスコに入れた100mlYPG
液体培地に接種し、30℃で20時間振とう培養し
た。Example 1 Preparation of DNA receptor cells Acetobacter aceti No.1023, FERM P
-7122 by mutation treatment with nitrosoguanidine (NTG) at a concentration of 100 μg/ml.
Acetic acid tolerance and ethanol oxidation ability obtained by natural mutation from aceti-10-8 (Ace r , Eth ++ , Pro - ) are reduced or deleted (Ace ss , Eth - ), and streptomycin resistance (Str r Acetobacter aceti 10-80S1 (Ace ss , Eth - , Pro - ,
100ml YPG containing Str r ) in a 500ml plate-necked flask.
It was inoculated into a liquid medium and cultured with shaking at 30°C for 20 hours.
培養液は0℃で、6000×gで、10分間遠心分離
し、集菌する。菌体は100mM NaCl及び5mM
MgCl2を含有する5mMトリス塩酸緩衝液(PH
7.6)の0.5倍容量で2回洗滌する。再び0℃6000
×gで、で5分間遠心分離し、集菌する。 The culture solution is centrifuged at 0° C. and 6000×g for 10 minutes to collect bacteria. Bacterial cells are 100mM NaCl and 5mM
5mM Tris-HCl buffer (PH
Wash twice with 0.5 times the volume of 7.6). 0℃6000 again
Centrifuge at ×g for 5 minutes to collect bacteria.
この菌体には0.4倍容量のCaCl2溶液(100mM
CaCl2、250mM KCl、5mM MgCl2、5mM
Tris−HCl、PH7.6)が加えられ、0℃で30分間
静置した後0℃で、6000×gで、5分間遠心分離
し、集菌する。 Add 0.4 times the volume of CaCl 2 solution (100mM
CaCl2 , 250mM KCl, 5mM MgCl2 , 5mM
Tris-HCl, pH 7.6) was added and left to stand at 0°C for 30 minutes, followed by centrifugation at 0°C and 6000 xg for 5 minutes to collect bacteria.
菌体には0.004倍容量の上記CaCl2溶液を添加し
DNA受容菌体懸濁液とした。 Add 0.004 times the volume of the above CaCl 2 solution to the bacterial cells.
A DNA receptor cell suspension was prepared.
実施例 2
プラスミドpTA5001(A)のプラスミドpTA5001
(B)の混在物の単離
アセトバクター・アセチNo.1023、FERM P−
7122を40mlのYPG培地に植菌し、30℃で一晩振
とう培養した。Example 2 Plasmid pTA5001 of plasmid pTA5001(A)
Isolation of contaminant (B) Acetobacter aceti No.1023, FERM P-
7122 was inoculated into 40 ml of YPG medium and cultured with shaking at 30°C overnight.
その後新らしいYPG培地4に1%て植え継
ぎさらに30℃時間振とう培養した。 Thereafter, the cells were subcultured into fresh YPG medium 4 at 1% and cultured with shaking at 30°C.
集菌後、TE緩衝液(20mM EDTA、50mM
トリス塩酸、PH8.0)で2回菌体を洗浄した。 After harvesting, add TE buffer (20mM EDTA, 50mM
The bacterial cells were washed twice with Tris-HCl (pH 8.0).
得られた湿菌体2gあたり2mlのTES緩衝液
(50mM トリス塩酸、20mM EDTA、25%シヨ
糖、PH8.0)を加え、菌体を懸濁し、4mlのリゾ
チーム液(0.25M トリス塩酸、リゾチーム2
%、PH8.0)をさらに加え、0℃で5分静置した。
次に0.25M EDTA液(PH8.0)を4ml加え、0℃
で5分間静置した後、37℃で20分間反応させた。
反応後、3mlの10%ラウリル硫酸ナトリウムを加
え、37℃で20分間静置後、5mlの5M食塩水を加
え、0℃で一夜静置した。48200×gで60分間遠
心分離をかけ、上清を分取した。次にこの上清に
最終濃度で10%になるようにポリエチレングリコ
ール6000を加え、4℃で一夜静置した後、3000×
gで10分間遠心分離し、沈澱物を得た。この沈澱
物を7mlのUC緩衝液(50mM トリス塩酸、
5mM EDTA、50mM NaCl、PH7.8)に溶解さ
せた後、最終濃度で500μg/mlになるようにエ
チジウムブロマイドを加え、さらに塩化セシウム
を加えて密度を1.57に合わせた。この溶液を15
℃、100000×gで40時間密度勾配遠心分離をおこ
なつた。遠心分離後、遠心チユーブに紫外線ラン
プで365nmの紫外線を照射することにより、染
色体バンドの下にあらわれるバンドをプラスミド
分画として分取した。次いで、分画液をイソプロ
パノールで処理し、エチジウムブロマイドを除去
した後、TE緩衝液(10mM トリス塩酸、1mM
EDTA、PH7.5)に対して透析した。これをプラ
スミド混在溶液とした。 Add 2ml of TES buffer (50mM Tris-HCl, 20mM EDTA, 25% sucrose, PH8.0) per 2g of the obtained wet bacterial cells to suspend the cells, and add 4ml of lysozyme solution (0.25M Tris-HCl, lysozyme). 2
%, PH8.0) was further added, and the mixture was allowed to stand at 0°C for 5 minutes.
Next, add 4 ml of 0.25M EDTA solution (PH8.0) and heat at 0℃.
After being allowed to stand for 5 minutes at 37°C, the reaction mixture was allowed to react for 20 minutes at 37°C.
After the reaction, 3 ml of 10% sodium lauryl sulfate was added and left to stand at 37°C for 20 minutes, then 5 ml of 5M saline was added and left to stand at 0°C overnight. Centrifugation was performed at 48,200×g for 60 minutes, and the supernatant was collected. Next, polyethylene glycol 6000 was added to this supernatant to a final concentration of 10%, and after standing at 4°C overnight, 3000x
A precipitate was obtained by centrifugation at g for 10 minutes. This precipitate was mixed with 7 ml of UC buffer (50mM Tris-HCl,
After dissolving in 5mM EDTA, 50mM NaCl, PH7.8), ethidium bromide was added to give a final concentration of 500 μg/ml, and cesium chloride was further added to adjust the density to 1.57. Add this solution to 15
Density gradient centrifugation was performed at 100,000 x g for 40 hours at °C. After centrifugation, the centrifugation tube was irradiated with 365 nm ultraviolet light using an ultraviolet lamp, and the band appearing below the chromosome band was separated as a plasmid fraction. The fractionated solution was then treated with isopropanol to remove ethidium bromide, and then treated with TE buffer (10mM Tris-HCl, 1mM
Dialyzed against EDTA, PH7.5). This was used as a plasmid mixed solution.
得られたプラスミド混在溶液中には2つの環状
プラスミドが混在しており、制限酵素による解析
の結果、第1図に示すプラスミドpTA5001(A)と
第2図に示すプラスミドpTA5001(B)であること
が明らかとなつた。 Two circular plasmids were found mixed in the resulting plasmid mixed solution, and as a result of analysis using restriction enzymes, it was determined that the plasmids were pTA5001(A) shown in Figure 1 and plasmid pTA5001(B) shown in Figure 2. It became clear.
すなわち前記で調製したプラスミド混在溶液に
対し、少なくとも5倍量過剰の制限酵素(EcoR
IおよびSal Iは宝酒造社製、Xho Iは、ベセ
スダ・リサーチ社製を使用した。)を常法に従が
つて各々の制限酵素の至適条件下で反応させた。
反応後、垂直型アガロースゲル電気泳動で分析し
た。即ち、1%のアガロースゲルを用い、トリス
酢酸緩衝液(40mM トリス、20mM 酢酸、
2mM EDTA、PH8.1)中で泳動させた。その後、
ゲルをエチジウムブロマイドの1μg/ml液に浸
して染色した。このゲルに紫外線を照射し、生成
断片を数を判断し、各断片の泳動距離から、各々
の分子量を算出した。分子量は、同一アガロース
上で同時に泳動したラムダフアージDNAのHind
切断で生成する分子量既知の各断片の泳動距離
から作成した標準線をもとに算出した。 That is, at least a 5-fold excess of restriction enzyme (EcoR) was added to the plasmid mixed solution prepared above.
I and Sal I were used from Takara Shuzo Co., Ltd., and Xho I was used from Bethesda Research Co., Ltd. ) were reacted according to a conventional method under optimal conditions for each restriction enzyme.
After the reaction, it was analyzed by vertical agarose gel electrophoresis. That is, using a 1% agarose gel, Tris acetate buffer (40mM Tris, 20mM acetic acid,
2mM EDTA, PH8.1). after that,
The gel was stained by soaking it in a 1 μg/ml solution of ethidium bromide. This gel was irradiated with ultraviolet rays, the number of generated fragments was determined, and the molecular weight of each fragment was calculated from the migration distance of each fragment. The molecular weight is the Hind value of lambda phage DNA that was run simultaneously on the same agarose.
Calculations were made based on a standard line created from the migration distance of each fragment of known molecular weight produced by cleavage.
各種制限酵素を単独で用いて得られた各断片及
び各制限酵素の2種以上を組合わせて用いた処理
によつて得られた各断片の断片数及び分子量など
からpTA5001(A)及びpTA5001(B)の第1図及び第
2図に示した制限酵素開裂地図が決定された。 pTA5001(A) and pTA5001( The restriction enzyme cleavage map shown in Figures 1 and 2 of B) was determined.
実施例 3
プラスミドpTA5001(A)とプラスミドpTA5001
(B)の混在物のベクターとしての利用
実施例2で得られたプラスミド混在溶液
(DNA量10μg)中に、大腸菌薬剤耐性ベクター
であるpACY177(カナマイシン耐性及びアンピシ
リン耐性;Journal of Bacteriology、134(3)、
1141−1156、1978)を持つ大腸菌(Escherichia
coli C600)から得たプラスミドpACYC177(第3
図に示す。DNA量2μg)を添加し、少なくとも
5倍量過剰の制限酵素Xho をI常法により至適
条件下で反応させ、反応終了後、等量のフエノー
ルを加え、激しく撹拌して制限酵素を失活させた
後、さらにエーテル抽出を充分行なつてフエノー
ルを除去し、さらに2倍量のエタノールを加えて
−80℃に1時間保持した後、15000rpmで5分間
遠心分離を行なつてDNAを沈降させ、さらに真
空乾燥してエタノールを除去した後、次に沈澱を
溶解後、常法によつてT4DNAリガーゼによる反
応を21℃で2時間行ない、さらに前記と同様にし
てエタノール沈澱、真空乾燥を行なつて得られた
沈澱をTE緩衝液0.1mlに溶解してキメラプラスミ
ド含有溶液を得た。Example 3 Plasmid pTA5001(A) and plasmid pTA5001
Use of (B) as a vector In the plasmid mixed solution (DNA amount 10 μg) obtained in Example 2, pACY177, an Escherichia coli drug-resistant vector (kanamycin resistance and ampicillin resistance; Journal of Bacteriology, 134(3) ),
1141−1156, 1978)
Plasmid pACYC177 (3rd generation) obtained from coli C600)
As shown in the figure. 2 μg of DNA) and react with at least 5 times excess of restriction enzyme After that, thoroughly perform ether extraction to remove phenol, add twice the amount of ethanol, hold at -80℃ for 1 hour, and centrifuge at 15,000 rpm for 5 minutes to precipitate the DNA. After further vacuum drying to remove ethanol, the precipitate was dissolved and a reaction using T4 DNA ligase was carried out at 21°C for 2 hours in the usual manner, followed by ethanol precipitation and vacuum drying in the same manner as above. The precipitate obtained was dissolved in 0.1 ml of TE buffer to obtain a solution containing the chimeric plasmid.
それぞれのキメラプラスミドはいずれもプラス
ミドpACYC177を含有してある。しかし、プラ
スミドpACYC177のカナイマイシン耐性部位に
xho I切断点があつて、そこが切断されている
ためにカナマイシン耐性は発現せず、アンピシリ
ン耐性のみが発現することになる。 Each chimeric plasmid contains plasmid pACYC177. However, the kanaimycin resistance site of plasmid pACYC177
Since there is an xho I breakpoint and this point is cleaved, kanamycin resistance is not expressed, and only ampicillin resistance is expressed.
次の実施例1で得られたDNA受容菌体懸濁液
0.2mlを用意し、これに上記そるぞれのキメラプ
ラスミド含有用液を加え、0℃で90分間ゆるやか
に撹しつつ、キメラプラスミドの直接導入を行な
つた。 DNA receptor cell suspension obtained in the following Example 1
0.2 ml of the solution was prepared, and each of the chimera plasmid-containing solutions mentioned above was added thereto, and the chimera plasmid was directly introduced while gently stirring at 0° C. for 90 minutes.
ここに得られたキメラプラスミド導入菌体を含
む液を3mlのYPG培地に移し、30℃、6時間振
とう培養を行なつた後、アンピシリン50μg/ml
添加したYPG培地(固体)上で30℃で5日間培
養し、9株のコロニーを得た。これらを10−
80S1−A1〜−A9と命名した。ことうち、10−
80S1−A1をアンピシリンを30μg/ml添加した
YPG液体培地で30℃、24時間振とう培養し、実
施例2の方法に従つてプラスミドを分離して解析
したところ、プラスミドpTA5001(A)とプラスミ
ドpTA5001(B)の混在物以外にこれらよりやや分
子量の大きいプラスミドが得られた。このプラス
ミドは先に導入したキメラプラスミドのうち、
pTA5001(A)とpACYC177がXho I切断部位を介
して連結したキメラプラスミドと認めらた。ま
た、アセトバクター・アセチ10−80S1はアンピ
シリン耐性を有しないが、10−80S1−A1はアン
ピシリン耐性を持つていることなどからもキメラ
プラスミドが導入され、形質転換が行なわれたこ
とが確認された。 The resulting solution containing the chimeric plasmid-introduced bacterial cells was transferred to 3 ml of YPG medium, cultured with shaking at 30°C for 6 hours, and then supplemented with ampicillin at 50 μg/ml.
The cells were cultured on the added YPG medium (solid) at 30°C for 5 days, and 9 colonies were obtained. These are 10−
They were named 80S1-A1 to -A9. Kotouchi, 10−
Ampicillin was added to 80S1-A1 at 30 μg/ml.
When cultured with shaking in YPG liquid medium at 30°C for 24 hours, the plasmids were separated and analyzed according to the method of Example 2. A plasmid with a large molecular weight was obtained. This plasmid is one of the previously introduced chimeric plasmids.
It was recognized as a chimeric plasmid in which pTA5001(A) and pACYC177 were linked via the Xho I cleavage site. In addition, Acetobacter aceti 10-80S1 does not have ampicillin resistance, but 10-80S1-A1 has ampicillin resistance, confirming that a chimeric plasmid was introduced and transformation was performed. .
同様にして、少なくとも10−80S1−A2〜−A6
はpTA5001(B)とpTACYC177が制限酵素Xho I
切断部位を介して連結したキメラプラスミドが導
入されていることが確認された。 Similarly, at least 10−80S1−A2 to −A6
pTA5001(B) and pTACYC177 are restriction enzyme Xho I
It was confirmed that the chimeric plasmid linked via the cleavage site had been introduced.
また、10−80S1−A1〜−A6の持つキメラプラ
スミドを再度10−80S1に前記と同様の方法で導
入したところ10−80S1−A1〜−A6の各キメラプ
ラスミドにおいて、1μgDNA量当りに換算して
105個前後のアンピシリン耐性を形質転換株が得
られた。 In addition, when the chimeric plasmids of 10-80S1-A1 to -A6 were reintroduced into 10-80S1 in the same manner as described above, the amount of chimeric plasmids of 10-80S1-A1 to -A6 was calculated per 1 μg DNA.
Approximately 10 5 transformed strains resistant to ampicillin were obtained.
第1図はプラスミドpTA5001(A)の制限酵素開
裂地図を示し、第2図はプラスミドpTA5001(B)
の制限酵素開裂地図を示し、第3図はプラスミド
pTCYC177の制限酵素開裂地図を示す。
E……EcoR Iによる切断部位、S……Sal I
による切断部位、X……Xho Iによる切断部位、
Km……カナマイシン耐性遺伝子、Am……アン
ピシリン耐性遺伝子。
Figure 1 shows the restriction enzyme cleavage map of plasmid pTA5001(A), and Figure 2 shows the restriction enzyme cleavage map of plasmid pTA5001(B).
Figure 3 shows the restriction enzyme cleavage map of the plasmid.
The restriction enzyme cleavage map of pTCYC177 is shown. E...cleavage site by EcoR I, S...Sal I
cleavage site by X...... cleavage site by Xho I,
Km...Kanamycin resistance gene, Am...Ampicillin resistance gene.
Claims (1)
されるプラスミドpTA5001(A)。 ただし、EはEcoR Iを意味し、SはSal Iを
意味し、XはXho Iを意味する。[Claims] 1. Plasmid pTA5001(A), which has a molecular weight of 23.5 kb and is shown in the restriction enzyme map below. However, E means EcoR I, S means Sal I, and X means Xho I.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58116149A JPS609488A (en) | 1983-06-29 | 1983-06-29 | Vector of acetic acid bacteria |
JP25431490A JPH03151881A (en) | 1983-06-29 | 1990-09-26 | Plasmid pta 5001 (b) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58116149A JPS609488A (en) | 1983-06-29 | 1983-06-29 | Vector of acetic acid bacteria |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP25431490A Division JPH03151881A (en) | 1983-06-29 | 1990-09-26 | Plasmid pta 5001 (b) |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS609488A JPS609488A (en) | 1985-01-18 |
JPH0363356B2 true JPH0363356B2 (en) | 1991-09-30 |
Family
ID=14679964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58116149A Granted JPS609488A (en) | 1983-06-29 | 1983-06-29 | Vector of acetic acid bacteria |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS609488A (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61139388A (en) * | 1984-12-11 | 1986-06-26 | Nakano Vinegar Co Ltd | Method of transformation of acetic acid bacteria belonging to genus gluconobacter using gene resistant to drug |
US4826768A (en) * | 1987-04-27 | 1989-05-02 | Texaco Inc. | Polyoxyalkylene glycol conversion to monocarboxylic acid |
JP2993700B2 (en) * | 1990-02-26 | 1999-12-20 | 株式会社中埜酢店 | Structural gene of cell membrane-bound alcohol dehydrogenase complex, plasmid containing it, and transformed acetic acid bacterium |
AU2003221332A1 (en) * | 2002-03-15 | 2003-09-29 | Mitsukan Group Corporation | Squalene-hopene cyclase gene of acetic acid bacterium, acetic acid bacterium bred with the use of the gene, and process for producing vinegar using the acetic acid bacterium |
AU2003289182A1 (en) * | 2002-12-09 | 2004-06-30 | Mitsukan Group Corporation | Gene improving temperature-tolerance of acetic acid bacterium, acetic acid bacterium bred using the gene and process for producing vinegar using the acetic acid bacterium |
JP4463200B2 (en) | 2003-03-12 | 2010-05-12 | 株式会社ミツカングループ本社 | Alcohol dehydrogenase gene of acetic acid bacteria |
-
1983
- 1983-06-29 JP JP58116149A patent/JPS609488A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS609488A (en) | 1985-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0363356B2 (en) | ||
JP2577876B2 (en) | Enzymes for the production of vitamin C precursors using genetically modified organisms and methods for their production | |
WO1995026404A1 (en) | Cell-surface polypeptide gene | |
JPH0669368B2 (en) | Method for transforming acetic acid bacterium | |
JPH0763371B2 (en) | RNA polymerase gene and microorganisms carrying the gene | |
JPH0371115B2 (en) | ||
EP0374771B1 (en) | Production method for PvuI restriction endonuclease | |
JP2857886B2 (en) | A Bacillus sp. DNA fragment containing an L-lactate dehydrogenase gene and a recombinant plasmid containing the same, and an L-lactate dehydrogenase gene and a recombinant plasmid containing the same. | |
JP2833793B2 (en) | Plasmid encoding heparinase, heparinase-producing strain carrying this plasmid, and method for producing heparinase | |
JP2634606B2 (en) | Plasmid pBY503 | |
JPS60188069A (en) | Transduction of cyclic dna into acetobacter | |
JPS61139387A (en) | Method of transformation of acetic acid bacteria belonging to genus gluconobacter | |
JPH0775582A (en) | Method of cloning and producing bglii restriction end nuclease and modified methylase | |
JP2518051B2 (en) | Method for producing AccI restricted endonuclease | |
JP2728784B2 (en) | Acetic acid bacterium, plasmid derived from the acetic acid bacterium, and shuttle vector constructed from the plasmid | |
JPH0679556B2 (en) | Plasmid | |
JPS59162883A (en) | Plasmid pmvx group and pmvy group | |
JP2671008B2 (en) | DNA encoding cyclomaltodextrin glucenotransferase, recombinant plasmid containing the same, and transformed microorganism containing the plasmid | |
SU1532585A1 (en) | Recombinant plasmide dna encoding methylase sso ii, and strain of escherichia coli bakteria as producer of methylase sso ii | |
JP2681634B2 (en) | New bacterial strain with enhanced thermostable liquefied amylase production capacity | |
JP2928265B2 (en) | DNA fragment, slightly acidic slightly cryogenic cellulase and method for producing the same | |
JPH0440896A (en) | New recombinant dna and production of sucrose-phosphorylase | |
JPH0479887A (en) | Dna fragment containing sucrose phosphorylase gene | |
JPH07255484A (en) | Plasmid pnc903 | |
JPH05244953A (en) | Plasmid pnc500 |